BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials – Video

Posted by Dr. Michael White, Published on November 2nd, 2012
()


BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials
BioSante Pharmaceuticals (BPAX) announced today that enrollment of subjects in the second of two pivotal Phase III safety and efficacy trials for LibiGel, a testosterone gel being developed to treat female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, has been completed. Enrollment in the first efficacy trial was completed in February. The trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement.From:TradeTheTrendViews:144 0ratingsTime:00:34More inNews Politics

Read the original here:

BioSante Pharma Completes Enrollment in Pivotal LibiGel Trials - Video

Contact Us Today

Enter Name (*)
Enter Email (*)
Enter Phone (*)
Select Program (*)
Select State (*)
Select your age (30+ only)
(*) - Required

After completing the contact form above, press the submit button. We will send you a confirmation email. Please check your email. For security purposes, please give us a call at 1-800-469-3343 if you don't receive an email.


men specialist hormones for bioidentical.webp


Related Post

How useful was this post?

Click on a smiley face to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Word Count: 105

Comments are closed.



testosterone chart low symptoms in women symptomatic.webp
side effects of testosterone supplementation.webp
how to increase free levels